89Bio Inc
ETNB14.840USD
0.0000.00%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
2.20BMarket Cap
LossP/E TTM
More Details of 89Bio Inc Company
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.
89Bio Inc Info
Ticker SymbolETNB
Company name89Bio Inc
IPO dateNov 11, 2019
CEOMr. Rohan Palekar
Number of employees93
Security typeOrdinary Share
Fiscal year-endNov 11
Address655 Montgomery Street
CitySAN FRANCISCO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94111
Phone14154329270
Websitehttps://www.89bio.com/
Ticker SymbolETNB
IPO dateNov 11, 2019
CEOMr. Rohan Palekar
Company Executives of 89Bio Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Quoc Le-Nguyen
Mr. Quoc Le-Nguyen
Chief Technical Operations Officer
Chief Technical Operations Officer
95.15K
-0.01%
Mr. Francis Willard Sarena, CPA., J.D.
Mr. Francis Willard Sarena, CPA., J.D.
Chief Operating Officer
Chief Operating Officer
72.56K
-0.01%
Mr. Ryan Martins
Mr. Ryan Martins
Chief Financial Officer
Chief Financial Officer
35.99K
-0.05%
Dr. Hank Mansbach, M.D.
Dr. Hank Mansbach, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Roger Brown
Roger Brown
Director
Director
--
--
Ms. Dara Pincas
Ms. Dara Pincas
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Quoc Le-Nguyen
Mr. Quoc Le-Nguyen
Chief Technical Operations Officer
Chief Technical Operations Officer
95.15K
-0.01%
Mr. Francis Willard Sarena, CPA., J.D.
Mr. Francis Willard Sarena, CPA., J.D.
Chief Operating Officer
Chief Operating Officer
72.56K
-0.01%
Mr. Ryan Martins
Mr. Ryan Martins
Chief Financial Officer
Chief Financial Officer
35.99K
-0.05%
Dr. Hank Mansbach, M.D.
Dr. Hank Mansbach, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Roger Brown
Roger Brown
Director
Director
--
--
Ms. Dara Pincas
Ms. Dara Pincas
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: 10 hours ago
Updated: 10 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Palekar (Rohan)
0.17%
Hayden (Michael Reuben)
0.11%
UBS Fund Management (Switzerland) AG
0.07%
Le-Nguyen (Quoc)
0.06%
Deka Vermögensmanagement GmbH
0.06%
Other
99.52%
Shareholders
Shareholders
Proportion
Palekar (Rohan)
0.17%
Hayden (Michael Reuben)
0.11%
UBS Fund Management (Switzerland) AG
0.07%
Le-Nguyen (Quoc)
0.06%
Deka Vermögensmanagement GmbH
0.06%
Other
99.52%
Shareholder Types
Shareholders
Proportion
Individual Investor
0.48%
Investment Advisor
0.19%
Investment Advisor/Hedge Fund
0.10%
Hedge Fund
0.05%
Research Firm
0.03%
Bank and Trust
0.03%
Other
99.13%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
412
111.97M
75.41%
-75.36M
2025Q3
398
151.66M
102.36%
-26.60M
2025Q2
415
160.66M
110.05%
+29.30K
2025Q1
438
159.25M
109.27%
+2.99M
2024Q4
410
127.02M
92.80%
-4.94M
2024Q3
400
110.52M
105.30%
-20.72M
2024Q2
393
109.45M
113.05%
-19.16M
2024Q1
388
104.01M
113.08%
-21.73M
2023Q4
375
99.22M
108.37%
+5.43M
2023Q3
350
77.31M
106.51%
-14.51M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
No Data
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Humankind US Stock ETF
0%
Invesco Raymond James SB-1 Equity ETF
0%
Global X Russell 2000 ETF
0%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares ESG Aware MSCI USA Small-Cap ETF
0%
Fidelity MSCI Health Care Index ETF
0%
ALPS Medical Breakthroughs ETF
0%
First Trust Innovation Leaders ETF
0%
View more
Humankind US Stock ETF
Proportion0%
Invesco Raymond James SB-1 Equity ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
FlexShares Morningstar US Market Factor Tilt Index Fund
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares ESG Aware MSCI USA Small-Cap ETF
Proportion0%
Fidelity MSCI Health Care Index ETF
Proportion0%
ALPS Medical Breakthroughs ETF
Proportion0%
First Trust Innovation Leaders ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
